Invivyd (IVVD) Receivables - Net (2024 - 2026)

Invivyd's (IVVD) quarterly Receivables - Net came in at $13.9 million in Q4 2025, up 27.45% YoY from $10.9 million in Q4 2024, and up 41.09% on a QoQ basis from $9.9 million in Q3 2025.

Invivyd (IVVD) Receivables - Net (2024 - 2026) Analysis & Trends

Invivyd (IVVD) has 2 years of Receivables - Net data on file, last reported at $13.9 million in Q4 2025.

  • Quarterly Receivables - Net rose 27.45% year-over-year to $13.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.9 million (up 27.45% YoY) and the FY2025 annual result came in at $13.9 million, up 27.63% from the prior year.
  • Receivables - Net improved to $13.9 million in Q4 2025, from $9.9 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $13.9 million in Q4 2025 to a low of $2.9 million in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Invivyd 212.23 Mn 52.15 Mn 13.01 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 11.22 Mn
Jun 30, 2026 11.22 Mn
Dec 31, 2025 13.90 Mn
Dec 31, 2025 13.90 Mn
Sep 30, 2025 9.85 Mn
Sep 30, 2025 9.85 Mn
Jun 30, 2025 8.70 Mn
Jun 30, 2025 8.70 Mn
Mar 31, 2025 8.56 Mn
Mar 31, 2025 8.56 Mn
Dec 31, 2024 10.91 Mn
Dec 31, 2024 10.91 Mn
Sep 30, 2024 8.20 Mn
Sep 30, 2024 8.20 Mn
Jun 30, 2024 2.90 Mn
Jun 30, 2024 2.90 Mn